Gymnema (Gymnema sylvestre): A Comprehensive Reference
1. Identity and Botanical Description
Scientific Nomenclature and Taxonomy
The accepted scientific name is Gymnema sylvestre (Retz.) Schult. Synonyms include Periploca sylvestris, and related species used in traditional contexts include Gymnema montanum and Gymnema inodorum. The plant belongs to the Gymnema genus of the Asclepiadaceae family (also classified within the Apocynaceae by some authorities). The genus name Gymnema is derived from the Greek gymnos ("naked") and nema ("thread"), a reference to the plant's thread-like climbing growth habit.
Common Names
It is known by numerous vernacular names, including Gurmar, Gurmarbooti, Kogilam, Madhunashini, Meshashringi, Meshavalli, Miracle plant, Periploca of the woods, Podapatri, Ram's horn, Sarkaraikolli, Shardunika, Sirukurinja, and Vishani. In Hindi, the name Gurmar translates as "sugar destroyer," a direct reference to its best-known effect of temporarily suppressing the ability to taste sweetness. In Sanskrit it is known as meshasringi, meaning "ram's horn."
Natural Source and Distribution
Gymnema sylvestre is a woody climbing shrub native to the tropical forests of India, Africa, and Australia. It can be found growing in tropical and subtropical regions, especially in parts of central and southern India, tropical Africa, and some parts of China, Malaysia, and Sri Lanka. Its distribution is worldwide and it is recognized in the traditional medicine of many countries, including Australia, Japan, and Vietnam.
Plant Morphology and Part Used
Gymnema sylvestre is a slow-growing, perennial, woody climber. The leaves are most commonly used, but the stem also appears to have some pharmacological activity. Dietary supplements and teas that contain gymnema are usually made from the leaves that grow on the vine.
Common Preparations and Dosage Forms
Extracts of Gymnema sylvestre are available over-the-counter in various forms and concentrations, including raw powders or capsules, alone or in combination with other herbal products or dietary supplements. The typical recommended dose in commercial products is 400 mg three times daily, though some products recommend as much as several grams daily. At present, there is little standardization of purity and concentration of extracts in gymnema products. Traditionally, the plant has also been consumed as a tea. In Ayurveda, dried and powdered leaves — and less commonly roots — were used in formulations to balance blood sugar and promote digestive health.
2. Traditional and Historical Use
Ayurvedic Medicine (India)
Practitioners of Ayurveda, India's traditional medicine, first used gymnema to treat diabetes almost two thousand years ago. The earliest textual mention appears in the ancient Charaka Samhita (circa 1000–200 BCE), where it is prescribed under the name Meṣaśṛṅgī for conditions described as "Madhumeha," a term now correlated with high blood sugar and excessive urination. Known as Shardunika, the plant has been a staple of Ayurvedic medicine for over 2,000 years, and the ancient Indian system of natural healing traditionally used it to help manage diabetes, high cholesterol, and digestive complaints, attributing to it anti-inflammatory, antioxidant, and hypoglycaemic properties.
In Eastern and Ayurvedic medicine, G. sylvestre leaves and extracts have been used to treat eye diseases, allergies, constipation, cough, dental caries, obesity, stomach ailments, and viral infections. G. sylvestre has also been used as an antioxidant, antimicrobial, and aphrodisiac.
Tribal and Regional Use in India
Various parts of the plant are used by different tribes in India, such as the Sahariya tribe of Madhya Pradesh, the Junglee Irulas of Nilgiri hills, the Kol tribe of Chhattisgarh, and the Nayaks of Karnataka, primarily to treat asthma, eye and gastric problems, parkinsonism, urinary problems, and diabetes.
The Sweet-Taste Suppression Tradition
One unique aspect of gymnema's traditional usage is its association with sweetness suppression. In Ayurvedic practices, chewing gymnema leaves was believed to temporarily hinder the ability to taste sweetness. Gymnemic acids are considered sweetness inhibitors, because after chewing the leaves, solutions sweetened with sugar taste like water. These acids suppress the sweetness of most sweeteners, including intense artificial sweeteners such as aspartame and natural sweeteners such as thaumatin.
Early Scientific Interest
In the 1920s, preliminary scientific studies found some evidence that gymnema leaves could reduce blood sugar levels, but nothing much came of this observation for decades. Research in India picked up again in the 1980s and 1990s, leading to the publication of promising preliminary studies in people. As early as 1930, the glucose-lowering effects of the plant were investigated.
Use in Japan
In Japan, 50 tons of G. sylvestre leaves are consumed annually for the purpose of weight loss.
3. Key Phytochemical Constituents
Primary Bioactive Classes
Gymnemic acids and gymnemasaponins are the major chemical constituents of this plant and are classified as oleanane saponins. Both oleanane and dammarane types of saponins are found in the leaves of Gymnema sylvestre. The leaves contain triterpene saponins belonging to the oleanane and dammarene classes; oleanane saponins include gymnemic acids and gymnemasaponins, while dammarene saponins are known as gymnemasides.
Gymnemic Acids
More than 20 homologs of gymnemic acid are known, with the central structure being the aglycone gymnemagenin. Gymnemagenins may inhibit the glycation of proteins and inhibit sodium-dependent glucose transporters that are found in high levels in brush-border membranes of intestinal epithelial cells. Gymnemic acids are glycosides of triterpene that suppress sweetness in humans. Specific gymnemic acid variants investigated include gymnemic acid I, II, X, deacylgymnemic acid, beta-amyrin acetate, longispinogenin, gymnemic acid II, gymnemasaponin VI, phytic acid, and gymnemic acid X.
Gurmarin
A 35 amino acid-long polypeptide called gurmarin has also been isolated; its pharmacology is related to sweet-taste-suppression in rodents, though its clinical relevance to diabetes pathology is not well established.
Other Constituents
Other plant constituents include flavones, anthraquinones, hentri-acontane, pentatriacontane, α- and β-chlorophylls, phytin, resins, d-quercitol, tartaric acid, formic acid, butyric acid, lupeol, β-amyrin-related glycosides, and stigmasterol. The plant extract also tests positive for alkaloids, and the leaves yield acidic glycosides and anthraquinones and their derivatives. Moreover, the plant has also been observed to contain tannins, quinones, flavonoids, and phenols.
The stems of Gymnema sylvestre have been investigated using chromatographic techniques and were found to contain several therapeutically important chemical compounds, including stigmasterol and triterpenoid saponin. Trace alkaloids identified include gymnamine and its hydroxyl derivative, 8-hydroxy gymnamine.
4. Mechanisms of Action
Sweet Taste Receptor Blockade
The taste-suppressing effect is caused by gymnemic acids, a group of triterpene saponins. These molecules are structurally similar to glucose, allowing them to interact directly with taste receptors on the tongue. Gymnemic acids bind to the sweet taste receptor — a protein complex known as the T1R2 and T1R3 heterodimer — occupying the binding sites and effectively blocking sugar molecules from activating the sweet taste pathway. This binding prevents the signal from being sent to the brain, resulting in reduced perception of sweetness. This temporary effect is highly selective; the extract does not interfere with the perception of other primary tastes, such as salty, sour, or bitter.
Inhibition of Intestinal Glucose Absorption
The mechanism of action also includes the inhibition of glucose absorption in the intestine by the saponin fraction of the herb. Gymnemic acids, due to their structural resemblance to glucose, occupy receptor sites in the absorptive external layers of the intestine; this competitive binding mechanism can slow down or block the transport of glucose molecules from the gut into the bloodstream. This action is thought to be related to the inhibition of sodium-dependent glucose transporters (SGLTs) in the intestinal lining.
Pancreatic Beta-Cell Effects and Insulin Secretion
Gymnema extracts may promote the production of insulin in weak or damaged beta cells and possibly increase the number of pancreatic beta cells and islets of Langerhans, according to histological assessments in diabetic animals. The plant has been reported to increase the activity of enzymes that are insulin-dependent, including hexokinase, glycogen synthetase, glyceraldehyde-3-phosphate dehydrogenase, and glucose-6-phosphate dehydrogenase, and to decrease the activity of insulin-independent enzymes such as glycogen phosphorylase, gluconeogenic enzymes, glucose-6-phosphatase, fructose-1,6-diphosphatase, and sorbitol dehydrogenase. When gymnema leaf extract is administered to a diabetic patient, there is stimulation of the pancreas, resulting in increased insulin release.
Insulin Sensitivity
One mechanism responsible for adult-onset diabetes mellitus is a form of insulin resistance attributed to the inability of insulin to enter cells via the insulin receptor. Gymnema may overcome this resistance, but further studies are required to confirm its validity and whether the effect is clinically relevant.
Lipid Metabolism
Gymnemic acid components have been found to increase fecal excretion of cholesterol, but further studies are needed to prove clinical significance in treating hypercholesterolemia. The plant's lipid-lowering potential is suggested to be due to the presence of acidic constituents such as flavonoids, saponins, and tannins.
Antioxidant Effects
Animal studies suggest that the antioxidant effects of gymnema occur via reduced lipid peroxidation in the serum, liver, and kidneys, and support hepatic glutathione peroxidase and serum glutamate pyruvate transaminase levels.
Multi-Target Synergy
A review of recent studies on the mechanism of action and biological activities of Gymnema sylvestre concluded that the antidiabetic effects of gymnema are the result of synergistic actions of several components on multiple targets involved in glucose metabolism.
5. Scientific Evidence by Area of Use
5.1 Blood Glucose Control — Type 2 Diabetes Mellitus
Overview of evidence: The most clinically studied application of gymnema is its use as an adjunct to conventional glucose-lowering therapy in type 2 diabetes mellitus (T2DM). The plant has been used in traditional medicine most notably to control blood glucose, which seems to have the strongest evidence of its historical uses. Use as a lipid-lowering agent, for weight loss, and for the inhibition of dental caries has also been investigated, primarily in rodent studies. However, limited clinical information is available to support the use of gymnema for any indication.
2021 Meta-analysis: A systematic review and meta-analysis aimed to evaluate the effect of Gymnema sylvestre supplementation on glycemic control in T2DM. Databases including PubMed, the Cochrane Library, Google Scholar, and ScienceDirect were searched through June 2020. The meta-analysis of 10 studies with a total of 419 participants showed that GS supplementation significantly reduced fasting blood glucose (SMD 1.57 mg/dL, 95% CI −2.22 to −0.93, p < 0.0001, I² = 90%), postprandial blood glucose (SMD 1.04 mg/dL, 95% CI −1.53 to −0.54, p < 0.0001, I² = 80%), and glycated haemoglobin (HbA1c) (SMD 3.91, 95% CI −7.35 to −0.16%, p < 0.0001, I² = 99%) compared to baseline. The very high heterogeneity (I² = 90–99%) across studies substantially limits the interpretability of pooled estimates.
Landmark 1990 human study (Baskaran et al.): Among 22 patients with type 2 diabetes on conventional oral drugs who were treated with addition of Gymnema sylvestre (400 mg daily) for 18–20 months, fasting blood glucose and HbA1c levels decreased in all patients and serum lipids improved; 5 patients were able to discontinue their conventional antidiabetic medications.
Randomized placebo-controlled trial in metabolic syndrome: A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients (without pharmacological treatment), aged 30–60 years, with a diagnosis of metabolic syndrome. Patients were randomly assigned to receive G. sylvestre or placebo twice daily before breakfast and dinner in 300 mg capsules for a total of 600 mg per day for 12 weeks. Outcomes evaluated included components of metabolic syndrome, body weight, BMI, total cholesterol, LDL, and VLDL.
2023 Lipid-focused RCT: A randomized controlled clinical trial on 75 patients with T2DM evaluated the effects of a combination of myo-inositol and d-chiro-inositol (40:1), α-lactalbumin, Gymnema sylvestre, and zinc on glucose and lipid profile. The intention-to-treat analysis displayed no significant differences in glucose parameters between the groups; however, the study group displayed reduced levels of total cholesterol (p = 0.01) and LDL (p = 0.03) after 3 months of supplementation. This trial used a multi-ingredient combination, making attribution of effects to gymnema specifically uncertain.
Evidence strength: The overall body of human evidence for blood glucose lowering in T2DM is promising but methodologically limited. Most studies are small, short-term, and conducted in populations already receiving antidiabetic drugs. The high statistical heterogeneity across meta-analysed studies, combined with variable extract preparations and a lack of large randomized trials, means that definitive conclusions cannot yet be drawn.
5.2 Blood Glucose Control — Type 1 Diabetes Mellitus
In a study in which 64 individuals with type 1 diabetes were treated with gymnema leaf extract for 6 to 30 months, results showed a reduction in plasma glucose level, reduced external insulin dose, and a significant reduction in HbA1c (p < 0.001). In the foundational 1990 Shanmugasundaram et al. study, the water-soluble extract GS4 was administered at 400 mg per day to 27 patients with insulin-dependent diabetes mellitus (IDDM) on insulin therapy. Insulin requirements came down together with fasting blood glucose, glycosylated haemoglobin (HbA1c), and glycosylated plasma protein levels. In type 1 diabetes, leaf extract has been reported to reduce insulin requirements and fasting glucose and to improve glycemic control. These studies are decades old, not placebo-controlled, and are preliminary in nature. The evidence base in type 1 diabetes is considerably weaker than in type 2.
5.3 Insulin Secretion from Human Islets
A study investigated the effects of a novel high molecular weight GS extract (termed OSA®) on glucose tolerance in insulin-resistant ob/ob mice and on insulin secretion and synthesis by isolated mouse islets. Single administration of OSA® (500 mg/kg) to ob/ob mice 30 minutes before an intraperitoneal glucose load improved their abnormal glucose tolerance. In vitro studies indicated that OSA® at 0.25 mg/mL initiated rapid and reversible increases in insulin secretion from isolated mouse islets at both substimulatory (2 mM) and stimulatory (20 mM) glucose concentrations. This study was conducted in animals and isolated islets and cannot be directly extrapolated to human clinical outcomes.
5.4 Lipid Profile and Cardiovascular Risk Factors
Meta-analysis evidence: A systematic review and meta-analysis reported that GS supplementation significantly decreased triglycerides (p < 0.001), total cholesterol (p < 0.001), LDL (p < 0.001), fasting blood sugar (p < 0.001), and diastolic blood pressure (p = 0.003). Limitations include notable heterogeneity, low quality of studies, and lack of diversity among research participants. The outcomes suggest that GS supplementation may improve cardiovascular risk factors.
Animal studies: In one study, Gymnema sylvestre leaf extract was administered to Wistar female rats introduced to hyperlipidemia by a high-fat diet. The extract significantly lowered cholesterol (p < 0.01), LDL (p < 0.01), and triglycerides (p < 0.01), and increased HDL (p < 0.001). In a rat study comparing gymnema to atorvastatin, GS decreased triglycerides, LDL, and VLDL significantly, but the effect was inferior to the standard drug atorvastatin.
Human observational data: A study in moderately obese people showed that gymnema extract decreased triglycerides and LDL cholesterol by 20.2% and 19%, respectively, while increasing HDL cholesterol levels by 22%. This finding comes from a single preliminary human study and requires replication in controlled trials.
Evidence strength: Lipid-lowering effects are well-documented in animal models and corroborated by some human data. However, evidence quality in humans is currently limited by small sample sizes, short durations, and the use of multi-ingredient formulations.
5.5 Sweet Taste Suppression and Sugar Craving Reduction
Gymnemic acids from Gymnema sylvestre selectively suppress taste responses to sweet compounds without affecting the perception of other taste elements. A crossover study investigated the effect of consuming a GS-containing mint on the desire to consume high-sugar sweet foods, comparing a dissolving tablet containing 4 mg of gymnemic acids with an isocaloric placebo in 56 healthy young men and women. Gymnema's key constituents suppress the perception of the sweet taste on the taste buds; if taken before food, the extract masks sweet detection and reduces desire for sweet foods and caloric intake for approximately 90 minutes after administration. The sweet-blocking effect is one of the most robustly reproduced acute phenomena associated with gymnema, though whether this translates into meaningful long-term reductions in sugar intake or body weight has not been rigorously demonstrated.
5.6 Weight Management and Obesity
Gymnema sylvestre extracts have been shown to aid weight loss in animals and humans, with one three-week study showing reduced body weight in rats given a water extract of Gymnema sylvestre. Early research suggests that taking a specific combination of Gymnema sylvestre extract, hydroxycitric acid, and niacin-bound chromium by mouth for 8 weeks might reduce body weight in people who are overweight or obese. The use of multi-ingredient products in this research makes it impossible to attribute weight-related effects to gymnema alone. Evidence in humans is at an early, preliminary stage.
5.7 Anti-Inflammatory and Antioxidant Activity
In vitro and in vivo investigations of Gymnema sylvestre have revealed multifarious pharmacological potentials, including anti-cancer, immunosuppressive, gastro-protective, hypoglycemic, anti-inflammatory, anti-infectious, and antidiabetic activities. G. sylvestre is also reported to possess antioxidant, antibiotic, anti-inflammatory, antiviral, gastro- and hepatoprotective, anticancer, and lipid-lowering activities. The evidence base for these additional activities remains largely in vitro or in animal models; clinical human data for anti-inflammatory or antioxidant endpoints are currently lacking.
5.8 Dental Caries Inhibition
A purified extract of Gymnema sylvestre has been reported to inhibit the production of a polysaccharide that is important in the formation of dental plaque implicated in dental caries, and the use of purified gymnemic acid as a method of preventing dental caries has been described in prior literature. The research on dental caries is largely preclinical and human evidence is lacking.
6. Associated Body Systems and Health Areas
- Endocrine / Metabolic system: Insulin secretion, pancreatic beta-cell function, glucose homeostasis, glycated hemoglobin reduction, metabolic syndrome.
- Cardiovascular system: Lipid modulation (LDL, HDL, triglycerides, VLDL), diastolic blood pressure, cholesterol metabolism.
- Gustatory / Nervous system: Sweet taste receptor blockade, reduction of palatability of sweet foods, craving modulation.
- Gastrointestinal system: Inhibition of intestinal glucose and fat absorption, digestive support.
- Hepatic system: Antioxidant and potential hepatoprotective effects reported in animal studies; rare case reports of hepatotoxicity (see Safety section).
- Immune/Inflammatory: Anti-inflammatory and antioxidant properties in preclinical models.
Gymnema extracts may have other antidiabetic actions, such as enhanced insulin secretion and inhibition of glucose absorption, as well as cholesterol-lowering, antioxidant, anti-inflammatory, antibacterial, and antineoplastic activities.
7. Dosage Forms and Doses Reported in Studies
Dosages used in research range from 400 mg per day up to 10 grams per day. The most frequent recommendation from manufacturers of GS supplements is to take a 100 mg tablet three to four times daily. Although this dosage is likely to be safe for most people, an evidence-based dosage has not yet been established.
- 400 mg/day (GS4 water-soluble leaf extract): Used in the landmark Shanmugasundaram et al. (1990) trial in 27 patients with insulin-dependent (type 1) diabetes on insulin therapy.
- 400 mg/day for 18–20 months: Used in the Baskaran et al. (1990) study of 22 patients with type 2 diabetes on oral antidiabetics.
- 600 mg/day (300 mg twice daily): Used in a randomized, double-blind, placebo-controlled trial in 24 patients with metabolic syndrome for 12 weeks.
- 800 mg/day (standardized to 25% gymnemic acids): Used in a preliminary U.S. trial in a group of type 1 and type 2 diabetics.
- 400–600 mg/day, standardized to 24% gymnemic acids: The dosage range cited in the Restorative Medicine clinical monograph as generally considered safe.
- 400–600 mg/day of an extract standardized to 24% gymnemic acid: Cited by an EBSCO Research Starters review as the typical clinical dosage.
- 600 mg/day: The dosage at which mild side effects including diarrhea, stomach cramps, and headache were reported in one study.
- Up to 6 g/day of a leaf preparation: Used in studies in healthy individuals without producing hypoglycemic episodes or notable problems.
- Traditional Ayurvedic use: 2–4 grams per day of the leaf powder was traditionally used.
8. Safety Considerations and Interactions
General Safety Profile
In small, rather short-term clinical studies of different preparations and concentrations of Gymnema sylvestre, adverse side effects were usually described as uncommon, unrelated to therapy, and minimal, with no changes in serum ALT, AST, GGT, or bilirubin levels. The effects of long-term use and of higher doses, however, have not been assessed in humans. Limited evidence from toxicological in vivo studies and human clinical studies suggested a lack of relevant adverse effects of this botanical.
Mild Adverse Effects
The main reported drawbacks of gymnema include mild side effects such as diarrhea and headaches, potential hypoglycemia, and limited safety data, particularly in humans. GS is considered safe at doses of up to 10 grams per day; the recommended daily dose of 400 mg is unlikely to produce any toxic effects. Mild side effects such as diarrhea, stomach cramps, and headache were reported in one study that used a dosage of 600 mg daily. Whether these effects are dose-related remains unclear.
Hypoglycemia Risk
Hypoglycemia is a potential risk of GS supplementation, since GS is used to lower blood sugar levels. People with diabetes who supplement with GS in addition to their medication should closely monitor blood glucose levels to avoid hypoglycemic episodes. Repeated hypoglycemic episodes have been noted as a cause for patient discontinuation in clinical trials; hypoglycemic effects have been observed in both diabetic and non-diabetic individuals.
Hepatotoxicity
Over the last 25 years, there have been rare, isolated reports of clinically apparent liver injury in patients taking Gymnema sylvestre. However, large case series and literature searches do not mention it as a potential cause of herb-induced liver injury. The NIH LiverTox database assigns a likelihood score of D (possible rare cause of clinically apparent liver injury). The chemical compounds in gymnema possibly responsible for liver injury are not known. The clinical features of the described cases suggest that the liver injury may be immunologically mediated. At least one published case report of liver toxicity related to the consumption of a gymnema tea could point to potential adulteration or contamination of the tea with hepatotoxic substances. In the cases that have been documented, the liver injury resolved on its own and did not progress to chronic damage.
Interactions with Antidiabetic Drugs
Human studies have provided indications that certain gymnema extracts may enhance the glucose-lowering effects of certain antidiabetic drugs. Considering the uncertainties in the composition of different gymnema preparations, potential herb–drug interactions, and the indications of glucose-lowering or hypoglycaemic effects, the use of gymnema-based food supplements in combination with authorised antidiabetic drugs may be associated with risks. Although no interactions have been formally reported, gymnema may decrease the required daily dose of insulin; therefore, people currently using insulin for the treatment of diabetes should discuss its use with a healthcare professional.
Interactions with Lipid-Lowering Agents
Caution is warranted in patients taking antilipemic agents because there may be a potential for additive effects. Reductions in levels of serum triglycerides, total cholesterol, VLDL, and LDL have been observed in animals following administration of gymnema.
Cytochrome P450 Interactions
It is thought that GS also impacts cytochrome P450, a protein in the liver that is important for drug metabolism. The clinical significance of this potential interaction has not been characterized in human studies.
Standardization and Product Variability
The safety evaluation of GS is complicated by a number of factors. Different preparations and different parts of the plant itself have different chemical compositions. This makes it difficult to research, as the available supplements are not all the same. Toxicology data is limited and not well reported in most of the available studies, and there are very few studies focusing on safety in humans.
EFSA Classification
In the EFSA Compendium of Botanicals (2012), G. sylvestre leaves were listed in Annex A (the "insufficient information" list), which includes botanicals appearing on a negative list or subject to restricted use in at least one European Member State, but for which not enough information on possible substances of concern or adverse effects could be found, or for which the information present could not be verified.
References
- Kanetkar P, Singhal R, Kamat M. "Gymnema sylvestre: A Memoir." J Clin Biochem Nutr. 2007. PMC2170951.
- Tiwari P, et al. "Comprehensive Review on Phytochemicals, Pharmacological and Clinical Potentials of Gymnema sylvestre." Frontiers in Pharmacology. 2019. PMC6830388.
- Tiwari P, et al. "Comprehensive Review on Phytochemicals, Pharmacological and Clinical Potentials of Gymnema sylvestre." Frontiers in Pharmacology. 2019.
- NIH National Library of Medicine. "Gymnema." LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Updated October 2024.
- Dang L, et al. "The effect of Gymnema sylvestre supplementation on glycemic control in type 2 diabetes patients: A systematic review and meta-analysis." Phytotherapy Research. 2021.
- Khosravi Z, et al. "The effects of Gymnema sylvestre supplementation on lipid profile, glycemic control, blood pressure, and anthropometric indices in adults: A systematic review and meta-analysis." PubMed. 2022.
- Zuñiga LY, et al. "Effect of Gymnema sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion." PubMed. 2017.
- Al-Romaiyan A, et al. "A novel extract of Gymnema sylvestre improves glucose tolerance in vivo and stimulates insulin secretion and synthesis in vitro." PubMed. 2012.
- Shanmugasundaram ERB, et al. "Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus." J Ethnopharmacol. 1990;30(3):281–294.
- Grasso S. "Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre." EFSA Supporting Publication. 2020. PMC7015520.
- "Consuming Gymnema sylvestre Reduces the Desire for High-Sugar Sweet Foods." PMC. 2020. PMC7230589.
- Pintaudi B, et al. "Combined Inositols, α-Lactalbumin, Gymnema Sylvestre and Zinc Improve the Lipid Metabolic Profile of Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial." Journal of Clinical Medicine. 2023.
- "Hypolipidaemic Effects of Gymnema sylvestre on High Fat Diet Induced Dyslipidaemia in Wistar Rats." J Clin Diagn Res. 2017. PMC5483703.
- Examine.com. "Gymnema sylvestre — Benefits, Dosage, and Side Effects." Examine Database.
- Examine.com. "What are Gymnema sylvestre's main drawbacks?" Examine FAQ.
- Restorative Medicine. "Gymnema (Gymnema sylvestre) — Clinical Monograph." Restorative Medicine Library.
- EBSCO Research Starters. "Gymnema's Therapeutic Uses." Complementary and Alternative Medicine Research Starters.
- ScienceDirect Topics. "Gymnema sylvestre — Overview." Pharmacology, Toxicology and Pharmaceutical Science.
- Auctores Online. "The use of Gymnema sylvestre in the treatment of diabetes: The available evidence and expert opinion." Current Clinical and Medical Education. 2024.
- Grieco A, et al. "Hidden Dangers: Herbal and Dietary Supplement Induced Hepatotoxicity." Livers. 2023.
Go back